KR102827626B1 - 멜록시캄을 포함하는 약학 조성물 - Google Patents
멜록시캄을 포함하는 약학 조성물 Download PDFInfo
- Publication number
- KR102827626B1 KR102827626B1 KR1020237021609A KR20237021609A KR102827626B1 KR 102827626 B1 KR102827626 B1 KR 102827626B1 KR 1020237021609 A KR1020237021609 A KR 1020237021609A KR 20237021609 A KR20237021609 A KR 20237021609A KR 102827626 B1 KR102827626 B1 KR 102827626B1
- Authority
- KR
- South Korea
- Prior art keywords
- meloxicam
- cyclodextrin
- pharmaceutical composition
- solid pharmaceutical
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cosmetics (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020257021329A KR20250099425A (ko) | 2015-02-10 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562114215P | 2015-02-10 | 2015-02-10 | |
| US62/114,215 | 2015-02-10 | ||
| US201562259993P | 2015-11-25 | 2015-11-25 | |
| US62/259,993 | 2015-11-25 | ||
| PCT/US2016/026991 WO2016131067A2 (en) | 2015-02-10 | 2016-04-11 | Pharmaceutical compositions comprising meloxicam |
| KR1020237007407A KR102550497B1 (ko) | 2015-02-10 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237007407A Division KR102550497B1 (ko) | 2015-02-10 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257021329A Division KR20250099425A (ko) | 2015-02-10 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230098923A KR20230098923A (ko) | 2023-07-04 |
| KR102827626B1 true KR102827626B1 (ko) | 2025-06-30 |
Family
ID=60389519
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237021609A Active KR102827626B1 (ko) | 2015-02-10 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
| KR1020257021329A Pending KR20250099425A (ko) | 2015-02-10 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
| KR1020227038441A Active KR102507663B1 (ko) | 2015-02-10 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
| KR1020227024833A Active KR102465027B1 (ko) | 2015-02-10 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
| KR1020217027341A Active KR102429352B1 (ko) | 2015-11-25 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
| KR1020227026291A Active KR102447080B1 (ko) | 2015-11-25 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
| KR1020177025448A Active KR102163404B1 (ko) | 2015-02-10 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
| KR1020237007407A Active KR102550497B1 (ko) | 2015-02-10 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
| KR1020207028181A Active KR102424013B1 (ko) | 2015-02-10 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257021329A Pending KR20250099425A (ko) | 2015-02-10 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
| KR1020227038441A Active KR102507663B1 (ko) | 2015-02-10 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
| KR1020227024833A Active KR102465027B1 (ko) | 2015-02-10 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
| KR1020217027341A Active KR102429352B1 (ko) | 2015-11-25 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
| KR1020227026291A Active KR102447080B1 (ko) | 2015-11-25 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
| KR1020177025448A Active KR102163404B1 (ko) | 2015-02-10 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
| KR1020237007407A Active KR102550497B1 (ko) | 2015-02-10 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
| KR1020207028181A Active KR102424013B1 (ko) | 2015-02-10 | 2016-04-11 | 멜록시캄을 포함하는 약학 조성물 |
Country Status (22)
| Country | Link |
|---|---|
| EP (3) | EP4470614A3 (https=) |
| JP (6) | JP6746612B2 (https=) |
| KR (9) | KR102827626B1 (https=) |
| CN (2) | CN113144218A (https=) |
| AU (4) | AU2016218992C1 (https=) |
| CA (4) | CA3278634A1 (https=) |
| CY (1) | CY1125193T1 (https=) |
| DK (1) | DK3256138T3 (https=) |
| ES (1) | ES2913288T3 (https=) |
| HU (1) | HUE058677T2 (https=) |
| IL (3) | IL316648A (https=) |
| LT (1) | LT3256138T (https=) |
| MX (2) | MX380762B (https=) |
| MY (1) | MY191574A (https=) |
| NZ (1) | NZ734233A (https=) |
| PL (1) | PL3256138T3 (https=) |
| PT (1) | PT3256138T (https=) |
| RS (1) | RS63260B1 (https=) |
| SG (2) | SG11201706123XA (https=) |
| SI (1) | SI3256138T1 (https=) |
| SM (1) | SMT202200194T1 (https=) |
| WO (1) | WO2016131067A2 (https=) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10532101B1 (en) | 2015-02-10 | 2020-01-14 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10780165B2 (en) | 2015-02-10 | 2020-09-22 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11013805B2 (en) | 2015-02-10 | 2021-05-25 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10821181B2 (en) | 2015-02-10 | 2020-11-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11602563B2 (en) | 2015-02-10 | 2023-03-14 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10933137B2 (en) | 2015-02-10 | 2021-03-02 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10537642B1 (en) | 2015-02-10 | 2020-01-21 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11013806B2 (en) | 2015-02-10 | 2021-05-25 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11045549B2 (en) | 2015-02-10 | 2021-06-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US12485176B2 (en) | 2015-02-10 | 2025-12-02 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| MY191574A (en) * | 2015-02-10 | 2022-06-30 | Axsome Therapeutics Inc | Pharmaceutical compositions comprising meloxicam |
| US10653777B2 (en) | 2015-02-10 | 2020-05-19 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10695430B2 (en) | 2015-02-10 | 2020-06-30 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10758618B2 (en) | 2015-02-10 | 2020-09-01 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11110173B2 (en) | 2015-02-10 | 2021-09-07 | Axsome Therapeutics, Inc | Pharmaceutical compositions comprising meloxicam |
| US10799588B2 (en) | 2015-02-10 | 2020-10-13 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10512692B2 (en) | 2015-02-10 | 2019-12-24 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10695429B2 (en) | 2015-02-10 | 2020-06-30 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10933136B2 (en) | 2015-02-10 | 2021-03-02 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10780166B2 (en) | 2015-02-10 | 2020-09-22 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11738085B2 (en) | 2015-02-10 | 2023-08-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10517950B1 (en) | 2015-02-10 | 2019-12-31 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US9821075B2 (en) | 2015-02-10 | 2017-11-21 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11607456B2 (en) | 2015-02-10 | 2023-03-21 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10729774B1 (en) | 2015-02-10 | 2020-08-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10722583B2 (en) | 2015-02-10 | 2020-07-28 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10058614B2 (en) | 2015-02-10 | 2018-08-28 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10729773B2 (en) | 2015-02-10 | 2020-08-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10702602B2 (en) | 2015-02-10 | 2020-07-07 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10821182B2 (en) | 2017-06-29 | 2020-11-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11801250B2 (en) | 2017-01-04 | 2023-10-31 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| SI3565550T1 (sl) * | 2017-01-04 | 2021-04-30 | Axsome Therapeutics, Inc. | Farmacevtske sestave, ki vsebujejo meloksikam in rizatriptan |
| US10940153B2 (en) | 2017-01-04 | 2021-03-09 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11433079B2 (en) | 2017-01-04 | 2022-09-06 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11433078B2 (en) | 2017-01-04 | 2022-09-06 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11266657B2 (en) | 2017-01-04 | 2022-03-08 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11471465B2 (en) | 2017-01-04 | 2022-10-18 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10905693B2 (en) | 2017-01-04 | 2021-02-02 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11806354B2 (en) | 2017-01-04 | 2023-11-07 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10729697B2 (en) | 2017-01-04 | 2020-08-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10729696B2 (en) | 2017-01-04 | 2020-08-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10583144B2 (en) | 2017-01-04 | 2020-03-10 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10894053B2 (en) | 2017-01-04 | 2021-01-19 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10561664B1 (en) | 2017-01-04 | 2020-02-18 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10583088B2 (en) | 2017-01-04 | 2020-03-10 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11617755B2 (en) | 2017-01-04 | 2023-04-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11207327B2 (en) | 2017-01-04 | 2021-12-28 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10471014B2 (en) | 2017-01-04 | 2019-11-12 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| EP4467600A3 (en) * | 2017-05-10 | 2025-03-12 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11510927B2 (en) | 2017-06-29 | 2022-11-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10688185B2 (en) | 2017-06-29 | 2020-06-23 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11865117B2 (en) | 2017-06-29 | 2024-01-09 | Axsome Therapeutics, Inc | Pharmaceutical compositions comprising meloxicam |
| US10918722B2 (en) | 2017-06-29 | 2021-02-16 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10758617B2 (en) | 2017-06-29 | 2020-09-01 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10987358B2 (en) | 2017-06-29 | 2021-04-27 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11185550B2 (en) | 2017-06-29 | 2021-11-30 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11219626B2 (en) | 2017-06-29 | 2022-01-11 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11617791B2 (en) | 2017-06-29 | 2023-04-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10512693B2 (en) | 2017-06-29 | 2019-12-24 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10688102B2 (en) | 2017-06-29 | 2020-06-23 | Axsome Therapeutics, Inc. | Combination treatment for migraine and other pain |
| US11617756B2 (en) | 2017-06-29 | 2023-04-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11759522B2 (en) | 2017-06-29 | 2023-09-19 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| KR102006777B1 (ko) | 2018-01-29 | 2019-10-08 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제 |
| KR102080023B1 (ko) | 2018-01-29 | 2020-02-21 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물 |
| KR102815027B1 (ko) * | 2018-07-03 | 2025-05-30 | 액섬 테라퓨틱스, 인크. | 멜록시캄을 포함하는 약학적 조성물 |
| US12251375B2 (en) | 2018-08-23 | 2025-03-18 | Chong Kun Dang Pharmaceutical Corp. | Pharmaceutical preparation having excellent dissolution properties, containing esomeprazole and sodium bicarbonate |
| US20230285306A1 (en) * | 2018-09-28 | 2023-09-14 | Axsome Therapeutics, Inc. | Dosage forms comprising active pharmaceutical ingredients |
| CA3213549A1 (en) * | 2019-02-06 | 2020-08-13 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| WO2021020771A1 (ko) * | 2019-07-26 | 2021-02-04 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물 |
| US20240058354A1 (en) | 2020-04-06 | 2024-02-22 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US12128052B2 (en) | 2020-05-28 | 2024-10-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| JP2023547736A (ja) * | 2020-11-06 | 2023-11-13 | マイラン ラボラトリーズ エルティーディー | メロキシカム含有医薬組成物 |
| US20250352552A1 (en) * | 2020-11-06 | 2025-11-20 | Mylan Laboratories Ltd | Pharmaceutical composition comprising meloxicam |
| US20250352478A1 (en) * | 2020-11-06 | 2025-11-20 | Mylan Laboratories Ltd | Pharmaceutical composition comprising meloxicam |
| JP7495340B2 (ja) * | 2020-12-16 | 2024-06-04 | 株式会社ファンケル | カルノシン酸含有固体組成物及びカルノシン酸の溶出促進方法 |
| EP4271386A4 (en) | 2020-12-31 | 2024-11-13 | Axsome Therapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM |
| US12370196B2 (en) | 2020-12-31 | 2025-07-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| CA3217139A1 (en) * | 2021-04-27 | 2022-11-03 | Sang-Jin Lee | Composition for preventing or treating muscular disease, comprising oxicam-based compound |
| US12005118B2 (en) | 2022-05-19 | 2024-06-11 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US12544383B1 (en) | 2025-01-30 | 2026-02-10 | Axsome Therapeutics, Inc. | Methods of treating migraines with a combination of a meloxicam and a rizatriptan |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3343295A (en) | 1994-08-12 | 1996-03-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Imidazopyridine salt |
| JP2896532B2 (ja) | 1994-08-13 | 1999-05-31 | ユーハン コーポレーション | 新規なピリミジン誘導体およびその製造方法 |
| ZA959469B (en) * | 1994-11-15 | 1996-05-15 | South African Druggists Ltd | Pharmaceutical composition |
| CA2301304A1 (en) * | 1997-08-27 | 1999-03-04 | Hexal Ag | New pharmaceutical compositions of meloxicam with improved solubility and bioavailability |
| AU2002305758B2 (en) * | 2001-06-01 | 2006-09-07 | Nuvo Pharmaceuticals (Ireland) Designated Activity Company | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| GB0320382D0 (en) * | 2003-08-30 | 2003-10-01 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre | Pharmaceutical compositions |
| AU2004274000B2 (en) | 2003-09-19 | 2009-07-30 | Drugtech Corporation | Pharmaceutical delivery system |
| WO2005076987A2 (en) * | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
| EP1744757A4 (en) * | 2004-05-04 | 2009-04-22 | Equitech Corp | IMPROVED ENHANCED COMPOSITION |
| EP1965774A2 (en) * | 2005-12-30 | 2008-09-10 | Cogentus Pharmaceuticals, Inc. | Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors |
| CN101646440A (zh) * | 2007-01-19 | 2010-02-10 | 武田制药北美公司 | 使用黄嘌呤氧化还原酶抑制剂和抗炎剂预防痛风突发或减少痛风突发次数的方法 |
| JP5681485B2 (ja) * | 2007-04-27 | 2015-03-11 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | クロピドグレルおよびスルホアルキルエーテルシクロデキストリンを含有する製剤ならびに使用方法 |
| WO2008157786A1 (en) * | 2007-06-20 | 2008-12-24 | Auspex Pharmaceutical, Inc. | Substituted n-aryl pyridinones as fibrotic inhibitors |
| CA2761455C (en) * | 2009-05-13 | 2018-06-12 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
| LT2616064T (lt) * | 2010-10-21 | 2019-11-25 | Rtu Pharmaceuticals Llc | Parengtos naudoti ketorolako kompozicijos |
| CN102526058A (zh) * | 2010-12-28 | 2012-07-04 | 秦引林 | 一种含氯诺昔康和埃索美拉唑消炎镇痛药物组合物 |
| WO2014161131A1 (en) * | 2013-04-01 | 2014-10-09 | Arissa Pharma | PREPARING AMORPHOUS MELOXICAM-β-CYCLODEXTRIN INCLUSION COMPLEX VIA SPRAY DRYING PROCESS |
| MY191574A (en) * | 2015-02-10 | 2022-06-30 | Axsome Therapeutics Inc | Pharmaceutical compositions comprising meloxicam |
-
2016
- 2016-04-11 MY MYPI2017702930A patent/MY191574A/en unknown
- 2016-04-11 WO PCT/US2016/026991 patent/WO2016131067A2/en not_active Ceased
- 2016-04-11 PL PL16750078.4T patent/PL3256138T3/pl unknown
- 2016-04-11 SG SG11201706123XA patent/SG11201706123XA/en unknown
- 2016-04-11 EP EP24205683.6A patent/EP4470614A3/en active Pending
- 2016-04-11 AU AU2016218992A patent/AU2016218992C1/en active Active
- 2016-04-11 PT PT167500784T patent/PT3256138T/pt unknown
- 2016-04-11 EP EP16750078.4A patent/EP3256138B1/en active Active
- 2016-04-11 NZ NZ734233A patent/NZ734233A/en unknown
- 2016-04-11 SG SG10202010157VA patent/SG10202010157VA/en unknown
- 2016-04-11 MX MX2017010304A patent/MX380762B/es unknown
- 2016-04-11 SI SI201631525T patent/SI3256138T1/sl unknown
- 2016-04-11 CN CN202110356434.5A patent/CN113144218A/zh active Pending
- 2016-04-11 SM SM20220194T patent/SMT202200194T1/it unknown
- 2016-04-11 JP JP2017560488A patent/JP6746612B2/ja active Active
- 2016-04-11 RS RS20220441A patent/RS63260B1/sr unknown
- 2016-04-11 KR KR1020237021609A patent/KR102827626B1/ko active Active
- 2016-04-11 KR KR1020257021329A patent/KR20250099425A/ko active Pending
- 2016-04-11 KR KR1020227038441A patent/KR102507663B1/ko active Active
- 2016-04-11 ES ES16750078T patent/ES2913288T3/es active Active
- 2016-04-11 HU HUE16750078A patent/HUE058677T2/hu unknown
- 2016-04-11 KR KR1020227024833A patent/KR102465027B1/ko active Active
- 2016-04-11 IL IL316648A patent/IL316648A/en unknown
- 2016-04-11 LT LTEPPCT/US2016/026991T patent/LT3256138T/lt unknown
- 2016-04-11 CA CA3278634A patent/CA3278634A1/en active Pending
- 2016-04-11 KR KR1020217027341A patent/KR102429352B1/ko active Active
- 2016-04-11 DK DK16750078.4T patent/DK3256138T3/da active
- 2016-04-11 KR KR1020227026291A patent/KR102447080B1/ko active Active
- 2016-04-11 EP EP22151689.1A patent/EP4008319B1/en active Active
- 2016-04-11 KR KR1020177025448A patent/KR102163404B1/ko active Active
- 2016-04-11 CA CA3204396A patent/CA3204396C/en active Active
- 2016-04-11 IL IL281863A patent/IL281863B2/en unknown
- 2016-04-11 CA CA2976272A patent/CA2976272C/en active Active
- 2016-04-11 CN CN201680009582.7A patent/CN107405359B/zh active Active
- 2016-04-11 KR KR1020237007407A patent/KR102550497B1/ko active Active
- 2016-04-11 KR KR1020207028181A patent/KR102424013B1/ko active Active
- 2016-04-11 CA CA3011562A patent/CA3011562C/en active Active
-
2017
- 2017-08-09 MX MX2021003230A patent/MX2021003230A/es unknown
- 2017-08-09 IL IL253925A patent/IL253925B/en active IP Right Grant
-
2019
- 2019-04-09 JP JP2019074133A patent/JP6842122B2/ja active Active
- 2019-05-13 AU AU2019203328A patent/AU2019203328C1/en active Active
-
2020
- 2020-07-16 AU AU2020205306A patent/AU2020205306C1/en active Active
-
2021
- 2021-02-04 JP JP2021016747A patent/JP7017275B2/ja active Active
-
2022
- 2022-01-20 JP JP2022007214A patent/JP7332202B2/ja active Active
- 2022-05-19 CY CY20221100344T patent/CY1125193T1/el unknown
- 2022-06-03 AU AU2022203861A patent/AU2022203861B2/en active Active
-
2023
- 2023-08-03 JP JP2023126893A patent/JP7721602B2/ja active Active
-
2025
- 2025-07-30 JP JP2025127530A patent/JP2025142338A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102827626B1 (ko) | 멜록시캄을 포함하는 약학 조성물 | |
| US10456471B2 (en) | Pharmaceutical compositions comprising meloxicam | |
| US9821075B2 (en) | Pharmaceutical compositions comprising meloxicam | |
| HK40119078A (en) | Pharmaceutical compositions comprising meloxicam | |
| HK40074468A (en) | Pharmaceutical compositions comprising meloxicam | |
| HK40074468B (en) | Pharmaceutical compositions comprising meloxicam |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R15-X000 | Change to inventor requested |
St.27 status event code: A-3-3-R10-R15-oth-X000 |
|
| R16-X000 | Change to inventor recorded |
St.27 status event code: A-3-3-R10-R16-oth-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| X701 | Decision to grant (after re-examination) | ||
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |